Dawson Chemical Co. v. Rohm & Haas Co.

448 U.S. 176, 100 S. Ct. 2601, 65 L. Ed. 2d 696, 1980 U.S. LEXIS 7
Supreme Court of the United States·Decided September 17, 1980·No. 79-669·Published·Cited by 196 cases

Opinions

[179]*179Mr. Justice Blackmtjn

delivered the opinion of the Court.

This ease presents an important question of statutory interpretation arising under the patent laws. The issue before us is whether the owner of a patent on a chemical process is guilty of patent misuse, and therefore is barred from seeking relief against contributory infringement of its patent rights, if it exploits the patent only in conjunction with the sale of an unpatented article that constitutes a material part of the invention and is not suited for commercial use outside the scope of the patent claims. The answer will determine whether respondent, the owner of a process patent on a chemical herbicide, may maintain an action for contributory infringement against other manufacturers of the chemical used in the process. To resolve this issue, we must construe the various provisions of 35 U. S. C. §271, which Congress enacted in 1952 to codify certain aspects of the doctrines of contributory infringement and patent misuse that previously had been developed by the judiciary.

I

The doctrines of contributory infringement and patent misuse have long and interrelated histories. The idea that a patentee should be able to obtain relief against those whose [180]*180acts facilitate infringement by others has been part of our law since Wallace v. Holmes, 29 F. Cas. 74 (No. 17,100) (CC Conn. 1871). The idea that a patentee should be denied relief against infringers if he has attempted illegally to extend the scope of his patent monopoly is of somewhat more recent origin, but it goes back at least as far as Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U. S. 502 (1917). The two concepts, contributory infringement and patent misuse, often are juxtaposed, because both concern the relationship between a patented invention and unpatented articles or elements that are needed for the invention to be practiced.

Both doctrines originally were developed by the courts. But in its 1952 codification of the patent laws Congress endeavored, at least in part, to substitute statutory precepts for the general judicial rules that had governed prior to that time. Its efforts find expression in 35 U. S. C. § 271:

“(a) Except as otherwise provided in this title, whoever without authority makes, uses or sells any patented invention, within the United States during the term of the patent therefor, infringes the patent.
“(b) Whoever actively induces infringement of a patent shall be liable as an infringer.
“(c) Whoever sells a component of a patented machine, manufacture, combination or composition, or a material or apparatus for use in practicing a patented process, constituting a material part of the invention, knowing the same to be especially made or especially adapted for use in an infringement of such patent, and not a staple article or commodity of commerce suitable for substantial noninfringing use, shall be liable as a contributory infringer.
“(d) No patent owner otherwise entitled to relief for infringement or contributory infringement of a patent shall be denied relief or deemed guilty of misuse or illegal extension of the patent right by reason of his having [181]*181done one or more of the following: (1) derived revenue from acts which if performed by another without his consent would constitute contributory infringement of the patent; (2) licensed or authorized another to perform acts which if performed without his consent would constitute contributory infringement of the patent; (3) sought to enforce his patent rights against infringement or contributory infringement.”

Of particular import to the present controversy are subsections (c) and (d). The former defines conduct that constitutes contributory infringement; the latter specifies conduct of the patentee that is not to be deemed misuse.

A

The catalyst for this litigation is a chemical compound known to scientists as “3, 4-diehloropropionanilide” and referred to in the chemical industry as “propanil.” In the late 1950’s, it was discovered that this compound had properties that made it useful as a selective, “post-emergence” herbicide particularly well suited for the cultivation of rice. If applied in the proper quantities, propanil kills weeds normally found in rice crops without adversely affecting the crops themselves. It thus permits spraying of general areas where the crops are already growing, and eliminates the necessity for hand weeding or flooding of the rice fields. Propanil is one of several herbicides that are commercially available for use in rice cultivation.

Efforts to obtain patent rights to propanil or its use as a herbicide have been continuous since the herbicidal qualities of the chemical first came to light. The initial contender for a patent monopoly for this chemical compound was the Monsanto Company. In 1957, Monsanto filed the first of three successive applications for a patent on propanil itself. After lengthy proceedings in the United States Patent Office, a patent, No. 3,382,280, finally was issued in 1968. It was de-[182]*182dared invalid, however, when Monsanto sought to enforce it by suing Rohm and Haas Company (Rohm & Haas), a competing manufacturer, for direct infringement. Monsanto Co. v. Rohm & Haas Co., 312 F. Supp. 778 (ED Pa. 1970), aff’d, 456 F. 2d 592 (CA3), cert. denied, 407 U. S. 934 (1972). The District Court held that propanil had been implicitly revealed in prior art dating as far back as 1902, even though its use as a herbicide had been discovered only recently. 312 F. Supp., at 787-790. Monsanto subsequently dedicated the patent to the public, and it is not a party to the present suit.

Invalidation of the Monsanto patent cleared the way for Rohm & Haas, respondent here, to obtain a patent on the method or process for applying propanil. This is the patent on which the present lawsuit is founded. Rohm & Haas’ efforts to obtain a propanil patent began in 1958. These efforts finally bore fruit when, on June 11, 1974, the United States Patent Office issued Patent No. 3,816,092 (the Wilson patent) to Harold F. Wilson and Dougal H. McRay.1 The patent contains several claims covering a method for applying propanil to inhibit the growth of undesirable plants in areas containing established crops.2' Rohm & Haas has been the sole owner of the patent since its issuance.

[183]*183Petitioners, too, are chemical manufacturers. They have manufactured and sold propanil for application to rice crops since before Rohm & Haas received its patent. They market the chemical in containers on which are printed directions for application in accordance with the method claimed in the Wilson patent. Petitioners did not cease manufacture and sale of propanil after that patent issued, despite knowledge that farmers purchasing their products would infringe on the patented method by applying the propanil to their crops.

Free access — add to your briefcase to read the full text and ask questions with AI

Dawson Chemical Co. v. Rohm & Haas Co., 448 U.S. 176, 100 S. Ct. 2601, 65 L. Ed. 2d 696, 1980 U.S. LEXIS 7 (1980).

448 U.S. 176 (Dawson Chemical Co. v. Rohm & Haas Co.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Thaler v. Iancu
E.D. Virginia, 2021
Cipla Ltd. v. Amgen Inc.
386 F. Supp. 3d 386 (D. Delaware, 2019)
Akamai Technologies, Inc. v. Limelight Networks, Inc.
786 F.3d 899 (Federal Circuit, 2015)
In re Cipro Cases I & II
348 P.3d 845 (California Supreme Court, 2015)
Gore Enterprise Holdings, Inc. v. Comptroller of the Treasury
87 A.3d 1263 (Court of Appeals of Maryland, 2014)
Doe v. Exxon Mobil Corp.
654 F.3d 11 (D.C. Circuit, 2011)
Princo Corp. v. International Trade Commission
616 F.3d 1318 (Federal Circuit, 2010)
In Re Gabapentin Patent Litigation
648 F. Supp. 2d 641 (D. New Jersey, 2009)
Ricoh Co., Ltd. v. Quanta Computer Inc.
550 F.3d 1325 (Federal Circuit, 2008)
In Re Ciprofloxacin Hydrochloride Antitrust Lit.
544 F.3d 1323 (Federal Circuit, 2008)
In re: Ralph Kimbro v.
Sixth Circuit, 2008
Pequignot v. Solo Cup Co.
540 F. Supp. 2d 649 (E.D. Virginia, 2008)
Veritas Operating Corp. v. Microsoft Corp.
562 F. Supp. 2d 1141 (W.D. Washington, 2008)
Pharmasterm Therapeutics, Inc. v. Viacell, Inc.
491 F.3d 1342 (Federal Circuit, 2007)
Oxford Gene Technology Ltd. v. Mergen Ltd.
345 F. Supp. 2d 444 (D. Delaware, 2004)
Engineered Products Co. v. Donaldson Co., Inc.
313 F. Supp. 2d 951 (N.D. Iowa, 2004)
Arthrocare Corp. v. Smith & Nephew, Inc.
310 F. Supp. 2d 638 (D. Delaware, 2004)